V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20211543 | 20134895 | 1.8 | null | Neo-adjuvant (N) | 2018-03-22 | 2018-04-09 | CARBO + FLUOROURACIL | 02 | null | BINIMETINIB + ENCORAFENIB | 100901858 |
| 20211578 | 20134896 | 1.46 | 81.9 | Curative (C) | 2019-03-22 | 2019-06-29 | Bevacizumab + Capecitabine | 02 | N | CISPLATIN + FLUOROURACIL + RT | 100774675 |
| 20211673 | 20134897 | 1.75 | 74 | Curative (C) | 2018-08-02 | 2018-08-05 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | LAROTRECTINIB | 100408345 |
| 20211713 | 20134898 | 1.8 | 10.8 | Neo-adjuvant (N) | 2019-12-31 | 2020-04-19 | Hydroxycarbamide | null | Y | BACILLUS CALMETTE-GUERIN | 100325217 |
| 20211883 | 20134899 | 1.38 | 67.8 | null | 2017-04-18 | 2017-05-10 | BCG Intravesical | null | null | EOF | 101557994 |
| 20211925 | 20134900 | 1.55 | 84 | null | 2021-10-01 | 2021-10-02 | Etoposide + Ifosfamide (5 days) | 02 | null | INTERAACT TRIAL | 100754310 |
| 20212058 | 20134902 | 1.47 | 60.9 | Palliative (P) | 2019-09-12 | 2019-09-22 | AXITINIB | 02 | null | OSIMERTINIB | 101481757 |
| 20212094 | 20134903 | 1.57 | 95.4 | Palliative (P) | 2019-09-25 | 2019-10-16 | Melphalan IV High dose | 02 | N | EOF | 100203168 |
| 20212109 | 20134904 | 1.65 | 76.2 | Adjuvant (A) | 2018-03-24 | 2018-03-24 | FCR | 02 | null | CISPLATIN + RT | 101414463 |
| 20212138 | 20134905 | 1.79 | 89.25 | null | null | 2017-12-14 | Pemetrexed | null | N | CAP + RT | 100461963 |
| 20212159 | 20134906 | null | null | Palliative (P) | 2016-07-06 | 2016-07-06 | null | 02 | null | CAPECITABINE + CETUXIMAB + OXALIPATIN | 100016305 |
| 20212242 | 20134907 | 1.61 | 94.8 | null | 2018-12-17 | 2019-01-12 | ECF | N | null | BINIMETINIB + ENCORAFENIB | 101149235 |
| 20212282 | 20134909 | 1.53 | 80.1 | Curative (C) | 2019-12-13 | 2019-12-13 | Bortezomib +/- Dexamethasone | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101382333 |
| 20212294 | 20134910 | null | 91.9 | Palliative (P) | 2017-05-17 | 2019-11-29 | CISPLATIN + FLUOROURACIL + Trastuzumab | N | null | RIPRETINIB | 100988487 |
| 20212591 | 20134911 | 1.69 | 97.45 | Palliative (P) | 2021-02-28 | 2021-03-13 | R-CHOEP | 02 | N | PEMETREXED | 101849529 |
| 20212931 | 20134912 | 1.55 | 47.6 | Palliative (P) | 2020-04-07 | 2020-04-23 | Bevacizumab + FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | BEAM | 101398419 |
| 20213063 | 20134914 | 1.57 | 80 | Palliative (P) | 2017-12-16 | 2018-03-18 | PHITT C SIOPEL-3HR | 99 | null | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 100186456 |
| 20213113 | 20134916 | 1.8 | 65.8 | Neo-adjuvant (N) | 2022-04-26 | 2022-04-27 | FCarboSt | N | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 101740336 |
| 20213129 | 20134917 | 1.79 | 74 | Palliative (P) | 2019-04-16 | 2019-04-24 | Gefitinib: 1 to 2 & 4 onwards | 02 | N | RIPRETINIB | 101865402 |
| 20213191 | 20134918 | 1.63 | 52 | Palliative (P) | 2021-07-26 | 2021-08-18 | Bevacizumab + FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | ALECTINIB | 101484197 |
| 20213555 | 20134919 | 1.6 | 77 | 03 | 2019-09-26 | 2019-09-28 | CHOP R - 21 days | 02 | null | CAPECITABINE + MITOMYCIN + RT | 101622761 |
| 20213584 | 20134920 | 1.84 | 67.7 | Curative (C) | 2022-02-12 | 2022-02-20 | ECF | 01 | N | MITOMYCIN | 100971313 |
| 20213606 | 20134921 | 1.92 | 69.85 | 03 | 2017-12-05 | 2018-04-10 | Dasatinib | 02 | null | STS RHABDO VIT0910 VINC IRINOTECAN | 101861283 |
| 20213947 | 20134924 | 1.82 | 70 | Neo-adjuvant (N) | 2018-06-21 | 2018-08-21 | IBRUTINIB | 02 | null | CARBOPLATIN + TEYSUNO | 101069901 |
| 20214103 | 20134925 | 1.57 | 72.7 | null | 2016-12-22 | 2016-12-22 | CISPLATIN + RALTITREXED + Trastuzumab | 01 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100473129 |
| 20214213 | 20134926 | 1.89 | 93.4 | null | 2019-10-24 | 2019-10-25 | Eribulin | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101392623 |
| 20214227 | 20134927 | 1.81 | 113.7 | null | 2021-03-27 | 2021-04-17 | Bevacizumab + Irinotecan + MdG | 02 | null | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 101716428 |
| 20214385 | 20134930 | 1.6 | 109.2 | Neo-adjuvant (N) | 2021-07-17 | 2021-08-21 | ATEZOLIZUMAB + NAB PACLITAXEL | null | N | NEO-AEGIS TRIAL | 100402622 |
| 20214544 | 20134931 | 1.8 | 88 | Palliative (P) | 2016-12-02 | 2016-12-02 | Bevacizumab + Irinotecan + MdG | 02 | null | EOF | 101807236 |
| 20214585 | 20134932 | 1.8 | 57.5 | Curative (C) | 2018-07-09 | 2018-07-19 | CAP | N | null | AZACITIDINE | 100678103 |
| 20214762 | 20134933 | 1.85 | 108 | Curative (C) | 2017-02-15 | 2019-07-26 | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | N | N | CARBOPLATIN + PEMETREXED | 100886212 |
| 20214764 | 20134934 | 0 | 61.25 | Curative (C) | 2017-07-03 | 2017-07-03 | Ribociclib | 01 | N | FOCUS4 TRIAL | 101579208 |
| 20214788 | 20134935 | 1.76 | 79.9 | Palliative (P) | null | 2019-08-14 | CHOP R - 21 days | N | null | CABAZITAXEL | 101481309 |
| 20214799 | 20134936 | 0 | 95.8 | Adjuvant (A) | 2018-04-29 | 2018-04-29 | BENDAMUSTINE + RITUXIMAB | null | N | OLAPARIB | 101000117 |
| 20214936 | 20134938 | 1.81 | 68.6 | Palliative (P) | 2018-10-20 | 2018-10-20 | null | N | N | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 101831960 |
| 20215076 | 20134940 | 1.6 | 107 | 03 | 2017-08-03 | 2017-08-07 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 02 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 100048467 |
| 20215121 | 20134941 | 1.79 | 84.3 | Palliative (P) | 2017-11-29 | 2017-11-29 | Ixazomib + Lenalidomide | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 100546650 |
| 20215258 | 20134942 | 1.68 | 58.2 | Palliative (P) | 2020-04-02 | 2020-04-13 | IBRUTINIB | 02 | null | CAPECITABINE + IRINOTECAN + PANITUMUMAB | 100417018 |
| 20215650 | 20134944 | 1.53 | 82.2 | null | 2019-12-04 | 2020-03-25 | CARBOPLATIN + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | DABRAFENIB | 100892795 |
| 20215671 | 20134945 | 1.72 | 81.5 | Palliative (P) | 2017-09-23 | 2017-09-24 | CAP + RT | 02 | N | FCIST | 101362840 |
| 20215844 | 20134946 | 1.65 | 92.8 | Curative (C) | 2019-01-15 | 2019-02-27 | VINCRISTINE | 02 | N | CYTARABINE + DAUNORUBICIN | 100420478 |
| 20215936 | 20134947 | 0 | 123 | Palliative (P) | 2018-11-05 | 2018-11-05 | Ifosfamide | 02 | N | CYTARABINE | 101630201 |
| 20216021 | 20134948 | 1.55 | 74.8 | 03 | 2019-01-04 | 2019-01-04 | Rucaparib | 02 | N | COSMIC TRIAL | 101029238 |
| 20216203 | 20134949 | 1.75 | 75.75 | Palliative (P) | 2019-12-21 | 2020-06-12 | Eribulin | N | N | CETUXIMAB + IRINOTECAN | 101603403 |
| 20216228 | 20134950 | 1.6 | 72.3 | null | 2017-02-27 | 2017-03-04 | Methotrexate intrathecal | 02 | null | CAP + RT | 100225055 |
| 20216245 | 20134951 | 1.81 | 59.55 | Palliative (P) | 2018-12-19 | 2018-12-27 | Bortezomib +/- Dexamethasone | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101232950 |
| 20216277 | 20134952 | 1.58 | 68.2 | null | 2018-11-20 | 2018-11-29 | BENDAMUSTINE + RITUXIMAB | 02 | N | HYDROXYCARBAMIDE | 101139226 |
| 20216345 | 20134953 | 1.65 | null | Curative (C) | 2017-05-21 | 2017-05-28 | null | 02 | N | GEMCITABINE + OXALIPLATIN | 101473051 |
| 20216410 | 20134954 | 1.57 | 80 | Neo-adjuvant (N) | 2017-03-31 | 2017-05-19 | Pemetrexed | null | N | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 101170759 |
| 20216432 | 20134955 | 1.73 | 56.5 | null | 2019-01-16 | 2019-01-19 | Cisplatin + Fluorouracil + RT 5day | 02 | N | OLAPARIB | 101148368 |